What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDA

The New York Times - Business:

Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.

Author: Pam Belluck

This post first appeared in The New York Times - Business. Read the original article.